Prognostic value of platelet-to-lymphocyte ratio in prostate cancer patients:a meta analysis
10.3969/j.issn.1009-8291.2023.01.012
- VernacularTitle:血小板与淋巴细胞比值对前列腺癌患者预后价值的meta分析
- Author:
Chenming GUO
1
;
Xing WANG
1
;
Baiqiang CUI
1
;
Yuhong LUO
2
;
Fenghai ZHOU
2
Author Information
1. Department of Urology, The First Clinical Medical College of Gansu University of Chinese Medicine, Lanzhou 730099
2. Department of Urology, Gansu Provincial People’s Hospital, Lanzhou 730013, China
- Publication Type:Journal Article
- Keywords:
prostate cancer;
platelet/lymphocyte ratio;
prognosis;
meta-analysis
- From:
Journal of Modern Urology
2023;28(1):50-58
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To evaluate the value of platelet-to-lymphocyte ratio (PLR) in the prognosis of prostate cancer. 【Methods】 Relevant studies were searched in CNKI, Wanfang, CBM, VIP, PubMed, Web of Science, Cochrane Library and Embase databases from inception to Dec.2021. The literature was screeded, data were extracted, and the quality was evaluated according to the inclusion and exclusion criteria. A meta-analysis by using the hazard risk (HR) and 95% confidence interval (CI) was adopted to assess the prognostic value of PLR. The data were analyzed with STATA 16.0 software. 【Results】 A total of 10 studies were included, involving 1 802 patients. For patients with high level of PLR, the overall survival (OS) (HR=1.70, 95%CI:1.25-2.30, P=0.001) and disease-free survival (DFS)(HR=1.44, 95%CI:1.15-1.81, P=0.002) were significantly shorter. 【Conclusion】 PLR is an independent risk factor affecting the long-term prognosis of prostate cancer patients. Pretreatment detection of PLR is meaningful in determining the prognosis.
